Syndax Pharmaceuticals SNDX Noncash Operating Lease Expense
Noncash Operating Lease Expense at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept sndx:NoncashOperatingLeaseExpense.
The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's noncash operating lease expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's noncash operating lease expense?
- Syndax Pharmaceuticals (SNDX) reported noncash operating lease expense of $130K in Q1 2026.
- How has Syndax Pharmaceuticals's noncash operating lease expense changed year-over-year?
- Syndax Pharmaceuticals's noncash operating lease expense decreased by 41.2% year-over-year, from $221K to $130K.
- What is the long-term trend for Syndax Pharmaceuticals's noncash operating lease expense?
- Over 4 years (2021 to 2025), Syndax Pharmaceuticals's noncash operating lease expense has grown at a 23.0% compound annual growth rate (CAGR), from $413K to $946K.
- What does noncash operating lease expense mean?
- This represents the portion of operating lease costs that does not involve an immediate cash outflow, typically associated with the amortization of right-of-use assets. It is added back to net income to reconcile to cash flow from operations.